alnylam
The Executive Director, Biostatistics at Alnylam is a senior scientific leader responsible for developing and executing statistical strategies across clinical development programs, providing guidance on trial design, regulatory strategy, and innovative methodologies. The role involves leadership in statistical methodology, regulatory interactions, and team development, with a focus on advancing drug development. This position can be hybrid, primarily based in Cambridge or Philadelphia.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
79% above the average for this role
Director, Biostatistics
Penfield Search
Associate Director, Biostatistics Consultant – Oncology
ClinChoice
Associate Director, Biostatistics
Sumitomo Pharma America, Inc.
Senior Director Biostatistics Head of Statistical Innovation & Methodology
Alnylam Pharmaceuticals
Associate Biostatistics Director - FSP (Permanent Home-based)
lifelancer
Biostatistics Director
Amgen